NF-κB as potential target in the treatment of melanoma

The RAS/MAP kinase pathway has attracted attention because activating mutations of the BRAF serine/threonine kinase was described in over 50% of melanomas. Very recently, selective and potent BRAF inhibitors have been developed. Several other signal transduction pathways have been found to be consti...

Descripción completa

Detalles Bibliográficos
Autores principales: Madonna, Gabriele, Ullman, Claudio Dansky, Gentilcore, Giusy, Palmieri, Giuseppe, Ascierto, Paolo Antonio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2012
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3338086/
https://www.ncbi.nlm.nih.gov/pubmed/22433222
http://dx.doi.org/10.1186/1479-5876-10-53

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3338086/
https://www.ncbi.nlm.nih.gov/pubmed/22433222
http://dx.doi.org/10.1186/1479-5876-10-53

Ejemplares similares